More on TEVA
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $36.62 |
|
|||
| Open | $36.40 | ||||
| 52 Wk High | $66.55 | ||||
| 52 Wk Low | $37.82 | ||||
| Day High | $36.93 | ||||
| Day Low | $36.13 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 7,401,238 | ||||
- S&P Global Ratings Upgrades Teva to BBB-, Marking Third Credit Rating Upgrade in Recent Months and Reflecting Strong Execution and Financial Discipline
- Teva Pharma (TEVA) PT Raised to $48 at UBS
- Form 8-K TEVA PHARMACEUTICAL INDU For: Sep 03
- Form 8-K TEVA PHARMACEUTICAL INDU For: Aug 31
- Teva's TEV '408 meets primary endpoint in celiac disease trial
- Teva in talks with Trump administration on Medicaid drug pricing
- Teva and Trump Administration Announce Intent to Reach Agreement around Affordable Medicines and Supply Chain Security for Patients in the U.S.
- Teva bids $57.5M for BioXcel agitation drug in bankruptcy sale
- Teva Announces Proposed Acquisition of a Novel Neuroscience Product Reinforcing Disciplined Business Development Approach Under Pivot to Growth Strategy
- Immuneering touts Phase 3 trial as FDA clears new pancreatic cancer drug
Entities mentioned with TEVA
- Definitive Agreement | View Related Stories »
- FDA | View Related Stories »
- Earnings | View Related Stories »
- Citi | View Related Stories »
- Options | View Related Stories »
- JPMorgan | View Related Stories »
- ARK | View Related Stories »
- Maynard Um | View Related Stories »
- Show More...
